Rimeporide, a first in class Na/H exchanger-1 inhibitor, ameliorates right ventricular dysfunction and pulmonary arterial hypertension in a SuHx model

Back

ESC Professional Premium Access

Rimeporide, a first in class Na/H exchanger-1 inhibitor, ameliorates right ventricular dysfunction and pulmonary arterial hypertension in a SuHx model

Session: Myocardial remodelling (1)

Topic: Cardiac Hypertrophy

Speaker: Doctor G. Milano (Lausanne, CH)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Giuseppina Milano

University Hospital Centre Vaudois (CHUV), Lausanne (Switzerland)

0 follower

7 more presentations in this session

  A high-throughput screening strategy identifies adenosine 5'-monophosphate as a novel enhancing molecule of the cardio-protective enzyme 5-oxoprolinase (OPLAH).

Speaker: Mr J. Esquivel Gaytan (Groningen, NL)

Melanocortin 1 receptor deficiency protects against pathological cardiac hypertrophy

Speaker: Ms A. Suominen (Turku, FI)

Betaine therapy of cardiac hypertrophy through inhibition of Hydroxy-carboxylic Acid Receptor 1 signaling

Speaker: Miss L. Yao (Nantong, CN)

ERBB4 stimulation mitigates atrial fibrillation and remodeling in a porcine DOCA model

Speaker: Doctor M. Tubeeckx (Antwerp, BE)

The anti-fibrotic effect of atrial natriuretic peptide depends on myocardial accumulation of the peptide in rat heart

Speaker: Professor S. Hatem (Paris, FR)

Access the full session

Myocardial remodelling (1)

Speakers: Doctor G. Milano, Mr J. Esquivel Gaytan, Ms A. Suominen, Miss L. Yao, Doctor M. Tubeeckx...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

Rimeporide, a first in class Na/H exchanger-1 inhibitor, ameliorates right ventricular dysfunction and pulmonary arterial hypertension in a SuHx model

About the speaker

Doctor Giuseppina Milano

7 more presentations in this session

A high-throughput screening strategy identifies adenosine 5'-monophosphate as a novel enhancing molecule of the cardio-protective enzyme 5-oxoprolinase (OPLAH).

Melanocortin 1 receptor deficiency protects against pathological cardiac hypertrophy

Betaine therapy of cardiac hypertrophy through inhibition of Hydroxy-carboxylic Acid Receptor 1 signaling

ERBB4 stimulation mitigates atrial fibrillation and remodeling in a porcine DOCA model

The anti-fibrotic effect of atrial natriuretic peptide depends on myocardial accumulation of the peptide in rat heart

Access the full session

Myocardial remodelling (1)

About the event

ESC Congress 2023

ESC 365 is supported by

  A high-throughput screening strategy identifies adenosine 5'-monophosphate as a novel enhancing molecule of the cardio-protective enzyme 5-oxoprolinase (OPLAH).